Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer.

被引：0
|
作者：
Morris, Michael J.
Solomon, Stephen Barnett
Durack, Jeremy C.
O'Donoghue, Joseph A.
Lyashchenko, Serge K.
Ruan Shutian
Carrasquillo, Jorge A.
Lewis, Jason Stuart
Martinez, Danny F.
Parada, Nicole A.
Keppler, Jennifer
Wu, Anna
Reuter, Victor E.
Weber, Wolfgang
Scher, Howard I.
Larson, Steven M.
Pandit-Taskar, Neeta
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Intervent Radiol & Image Guided Therapies, New York, NY 10021 USA
[3] ImaginAb Inc, Inglewood, CA USA
[4] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
220
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Slovin, Susan F.
    Wang, Xiuyan
    Hullings, Melanie
    Arauz, Gabrielle
    Bartido, Shirley
    Lewis, Jason Stuart
    Schoeder, Heiko
    Zanzonico, Pat
    Scher, Howard I.
    Riviere, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase I trial of fractionated-dose 177Lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody. J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC)
    Tagawa, S. T.
    Akhtar, N. H.
    Nikolopoulou, A.
    Vallabhajosula, S.
    Osborne, J.
    Beltran, H.
    Kahn, R.
    Goldsmith, S. J.
    Nanus, D. M.
    Bander, N. H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S702
  • [23] Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
    de Kouchkovsky, Ivan
    Zhang, Li
    Huang, Jiaoti
    Trepka, Kai
    Chou, Jonathan
    Foye, Adam
    Shui, David
    Wong, Chris
    Friedl, Verena
    Weinstein, Alana
    Hope, Thomas A.
    Quigley, David A.
    Stuart, Josh
    Beer, Tomasz M.
    Reiter, Robert Evan
    Gleave, Martin E.
    Evans, Christopher P.
    Feng, Felix Y.
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [24] Prostate-specific membrane antigen (PSMA) expression in patients with metastatic triple negative breast cancer: Initial results of the PRISMA study
    Marta, Guilherme Nader
    Wimana, Zena
    Taraji, Loubna
    Aftimos, Philippe Georges
    Piccart-Gebhart, Martine J.
    Flamen, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Slovin, Susan F.
    Wang, Xiuyan
    Hullings, Melanie
    Arauz, Gabrielle
    Bartido, Shirley
    Lewis, Jason Stuart
    Schoeder, Heiko
    Zanzonico, Pat
    Scher, Howard I.
    Sadelain, Michel
    Riviere, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [26] Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer
    Niaz, Muhammad Junaid
    Batra, Jaspreet S.
    Walsh, Ryan D.
    Vallabhajosula, Shankar
    Jhanwar, Yuliya S.
    Molina, Ana M.
    Nanus, David M.
    Osborne, Joseph R.
    Bander, Neil H.
    Tagawa, Scott T.
    ONCOLOGIST, 2020, 25 (06): : 477 - +
  • [27] Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591
    Morris, Michael J.
    Pandit-Taskar, Neeta
    Tagawa, Scott T.
    Nanus, David M.
    Solomon, Stephen Barnett
    Carrasquillo, Jorge A.
    Reuter, Victor E.
    Lewis, Jason Stuart
    Beylergil, Volkan
    O' Donoghue, Joseph A.
    Lyashchenko, Serge K.
    Martinez, Danny F.
    Curtis, Kristen Rebecca
    Durack, Jeremy C.
    Cheal, Sarah M.
    Bander, Neil Harrison
    Scher, Howard I.
    Larson, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [28] Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
    Sue Ping Thang
    Violet, John
    Sandhu, Shahneen
    Iravani, Amir
    Akhurst, Tim
    Kong, Grace
    Kumar, Aravind Ravi
    Murphy, Declan G.
    Williams, Scott G.
    Hicks, Rodney J.
    Hofman, Michael S.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 670 - 676
  • [29] CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
    Farwell, Michael D.
    Gamache, Raymond F.
    Babazada, Hasan
    Hellmann, Matthew D.
    Harding, James J.
    Korn, Ron
    Mascioni, Alessandro
    Le, William
    Wilson, Ian
    Gordon, Michael S.
    Wu, Anna M.
    Ulaner, Gary A.
    Wolchok, Jedd D.
    Postow, Michael A.
    Pandit-Taskar, Neeta
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (05) : 720 - 726
  • [30] A PHASE 2 TRIAL OF PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN TAXANE-TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Petrylak, Daniel
    Smith, David C.
    Appleman, Leonard J.
    Fleming, Mark
    Hussain, Arif
    Dreicer, Robert
    Sartor, A. Oliver
    Shore, Neil
    Vogelzang, Nicholas J.
    Youssoufian, Hagop
    Olson, William
    Stambler, Nancy
    Huang, Kathleen
    Israel, Robert
    JOURNAL OF UROLOGY, 2014, 191 (04): : E813 - E814
12345